Company Overview
Company Type: Private Company
Website: www.borealgenomics.com
Global Number of Employees (Latest): -
Year Founded: 2007
Total Amount Raised (CAD mm)†: 25.66
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Boreal Genomics Inc. develops and markets technologies for blood-based detection and monitoring of circulating tumor DNA. It offers OnTarget, a tool for the detection and quantification of tumor mutations in plasma or tissue; Aurora that purifies and concentrates nucleic acids from a range of samples, including life sciences research, soil and environmental, agriculture biotechnology, and forensics. The company was founded in 2007 and is headquartered in Los Altos, California with an additional office in Vancouver, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Global Number of Employees (Latest)
-
Net Debt
-
U.S. Number of Employees 2014
 10
U.S. Number of Employees 2013
-
U.S. Last Year Employee Growth %
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Marziali, Andre 
Founder, Chief Scientific Officer and Director
Pel, Joel
Head of Technology Development
Broemeling, David
Vice President of Marketing & Business Development
Wiggin, Matthew
Head of Product Development

Key Board Members
Name
Title
Roelofs, Nicolas Henry
Chairman
Marziali, Andre 
Founder, Chief Scientific Officer and Director
Castelein, Caley M.
Director
Crandell, Keith L.
Director
Meek, Isaac
Member of Advisory Board


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
5150 El Camino Real | Los Altos, CA | 94022 | United States
Phone: 650-316-8620   Fax: 650-316-8620

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
Arch Venture Partners, L.P.
Mar-31-2010
Unknown
-
Series B
David Cruikshank, Keith Crandell
GrowthWorks Ltd.
Mar-31-2010
Minority
-
Series B
-
In-Q-Tel, Inc.
Mar-31-2010
Minority
-
Series B
-
Kearny Venture Partners
Mar-31-2010
Unknown
-
Series B
Caley Castelein
B.C. Renaissance Capital Fund Ltd.
-
Unknown
-
-
-

Prior Investors
Iif Management Company, LLC, Pender Private Equity Fund Management Inc (Tony Rautava)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-30-2013
Oct-4-2013
Private Placement
Target
Boreal Genomics Inc.
Arch Venture Partners, L.P.,Kearny Venture Partners

18.00
Mar-31-2010
Dec-15-2010
Private Placement
Target
Boreal Genomics Inc.
Arch Venture Partners, L.P.,Kearny Venture Partners,GrowthWorks Ltd.,In-Q-Tel, Inc. Buyer Funds:In-Q-Tel

6.90
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jan-23-2018
Company Conference Presentations
Boreal Genomics Inc. Presents at Precision Medicine World Conference - Silicon Valley, Jan-23-2018 01:45 PM
Nov-30-2016
Client Announcements
Trovagene and Boreal Genomics Announce Strategic Partnership
Oct-04-2013
Private Placements
Boreal Genomics Inc. announced that it has received $18 million in funding from Arch Venture Partners, L.P., Kearny Venture Partners, and from other investors.
Sep-30-2013
Private Placements
Boreal Genomics Inc. announced that it expects to receive $18 million in funding.
Dec-15-2010
Private Placements
Boreal Genomics Inc. announced that it has received $6.9 million in funding from Arch Venture Partners, L.P., In-Q-Tel, Inc., Kearny Venture Partners, Matrix Asset Management Inc..


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 08:26 AM
Boreal Genomics Inc.
Boreal Genomics Inc
Reports
16
GlobalData

Jun 14, 2023 05:00 AM
Boreal Genomics Inc.
Boreal Genomics Inc
Reports
16
GlobalData

Mar 17, 2023 04:16 AM
Boreal Genomics Inc.
Boreal Genomics Inc
Reports
16
GlobalData

Dec 13, 2022 05:08 AM
Boreal Genomics Inc.
Boreal Genomics Inc
Reports
23
GlobalData

Sep 16, 2022 07:42 PM
Boreal Genomics Inc.
Boreal Genomics Inc
Reports
23
GlobalData

Jun 17, 2022 03:16 AM
Boreal Genomics Inc.
Boreal Genomics Inc
Reports
23
GlobalData

Mar 13, 2022 02:44 AM
Boreal Genomics Inc.
Boreal Genomics Inc
Reports
23
GlobalData

Dec 15, 2021 02:26 AM
Boreal Genomics Inc.
Boreal Genomics Inc
Reports
21
GlobalData

Sep 14, 2021 09:32 AM
Boreal Genomics Inc.
Boreal Genomics Inc
Reports
15
GlobalData

Jun 19, 2021 04:40 PM
Boreal Genomics Inc.
Boreal Genomics Inc
Reports
15


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Roelofs, Nicolas Henry
Chairman
650-316-8620
650-316-8620

Marziali, Andre 
Founder, Chief Scientific Officer and Director
650-316-8620
650-316-8620

Castelein, Caley M.
Director
650-316-8620
650-316-8620
-
Crandell, Keith L.
Director
650-316-8620
650-316-8620

Meek, Isaac
Member of Advisory Board
650-316-8620
650-316-8620
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Marziali, Andre 
Founder, Chief Scientific Officer and Director
650-316-8620
650-316-8620

Pel, Joel
Head of Technology Development
650-316-8620
650-316-8620
-
Broemeling, David
Vice President of Marketing & Business Development
650-316-8620
650-316-8620
david@borealgenomics.com
Wiggin, Matthew
Head of Product Development
650-316-8620
650-316-8620
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
